TREVI THERAPEUTICS INC (TRVI) Stock Price, Quote, News and Overview
NASDAQ:TRVI - Nasdaq - US89532M1018 - Common Stock - Currency: USD
TRVI Quote, Performance and Key Statistics
6.35
+0.08 (+1.28%)
The current stock price of TRVI is 6.35 USD. In the past month the price decreased by -1.85%. In the past year, price increased by 128.42%.
TRVI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 66.13 | 815.02B | ||
| JNJ | JOHNSON & JOHNSON | 15.42 | 373.36B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.05 | 278.02B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14 | 219.57B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.76 | 215.63B | ||
| MRK | MERCK & CO. INC. | 10.45 | 200.91B | ||
| SNY | SANOFI-ADR | 11.95 | 131.07B | ||
| PFE | PFIZER INC | 7.32 | 129.20B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 42.71 | 99.07B | ||
| GSK | GSK PLC-SPON ADR | 8.62 | 75.99B | ||
| ZTS | ZOETIS INC | 25.73 | 67.93B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.15 | 47.56B |
Related stock screener links
About TRVI
Company Profile
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. The company is headquartered in New Haven, Connecticut and currently employs 25 full-time employees. The company went IPO on 2019-05-07. The firm is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. The company is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. The company has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Company Info
TREVI THERAPEUTICS INC
195 Church St Fl 14
New Haven CONNECTICUT 06510 US
CEO: Jennifer Good
Employees: 26
Company Website: https://www.trevitherapeutics.com/
Investor Relations: https://ir.trevitherapeutics.com/
Phone: 12033042499
TREVI THERAPEUTICS INC / TRVI FAQ
What is the stock price of TREVI THERAPEUTICS INC today?
The current stock price of TRVI is 6.35 USD. The price increased by 1.28% in the last trading session.
What is the ticker symbol for TREVI THERAPEUTICS INC stock?
The exchange symbol of TREVI THERAPEUTICS INC is TRVI and it is listed on the Nasdaq exchange.
On which exchange is TRVI stock listed?
TRVI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TREVI THERAPEUTICS INC stock?
15 analysts have analysed TRVI and the average price target is 20.23 USD. This implies a price increase of 218.58% is expected in the next year compared to the current price of 6.35. Check the TREVI THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TREVI THERAPEUTICS INC worth?
TREVI THERAPEUTICS INC (TRVI) has a market capitalization of 613.92M USD. This makes TRVI a Small Cap stock.
How many employees does TREVI THERAPEUTICS INC have?
TREVI THERAPEUTICS INC (TRVI) currently has 26 employees.
What are the support and resistance levels for TREVI THERAPEUTICS INC (TRVI) stock?
TREVI THERAPEUTICS INC (TRVI) has a support level at 6.01. Check the full technical report for a detailed analysis of TRVI support and resistance levels.
Should I buy TREVI THERAPEUTICS INC (TRVI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TRVI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TRVI, evaluating the profitability, health, valuation and growth aspects
- TREVI THERAPEUTICS INC (TRVI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TREVI THERAPEUTICS INC (TRVI) Sales and EPS estimates to see what analysts future expectations are.
- TREVI THERAPEUTICS INC (TRVI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TREVI THERAPEUTICS INC (TRVI) Insider and Institutional Ownership to learn about the owners and their transactions.
- TREVI THERAPEUTICS INC (TRVI) Stock Chart to make your own analysis
- TREVI THERAPEUTICS INC (TRVI) Latest news and press-releases to stay up to date.
Does TREVI THERAPEUTICS INC (TRVI) stock pay dividends?
TRVI does not pay a dividend.
When does TREVI THERAPEUTICS INC (TRVI) report earnings?
TREVI THERAPEUTICS INC (TRVI) will report earnings on 2025-05-08.
What is the Price/Earnings (PE) ratio of TREVI THERAPEUTICS INC (TRVI)?
TREVI THERAPEUTICS INC (TRVI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.47).
What is the Short Interest ratio of TREVI THERAPEUTICS INC (TRVI) stock?
The outstanding short interest for TREVI THERAPEUTICS INC (TRVI) is 4.97% of its float. Check the ownership tab for more information on the TRVI short interest.
TRVI Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TRVI. When comparing the yearly performance of all stocks, TRVI is one of the better performing stocks in the market, outperforming 98.41% of all stocks.
TRVI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TRVI. TRVI has a great financial health rating, but its profitability evaluates not so good.
TRVI Financial Highlights
Over the last trailing twelve months TRVI reported a non-GAAP Earnings per Share(EPS) of -0.47. The EPS decreased by -62.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.2% | ||
| ROE | -48.08% | ||
| Debt/Equity | 0 |
TRVI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to TRVI. The Buy consensus is the average rating of analysts ratings from 15 analysts.